Mirococept
Mirococept Uses, Dosage, Side Effects, Food Interaction and all others data.
Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation. It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the naturally occurring membrane-bound myristoyl-electrostatic switch peptide.
| Trade Name | Mirococept |
| Generic | Mirococept |
| Mirococept Other Names | Mirococept |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in transplant (rejection), kidney disease, and rheumatoid arthritis.
How Mirococept works
Mirococept comprises the C3/C5 convertase-inhibiting region of CR1. This complement inhibitory domains of CR1 (in APT070) contain C3b-binding sites that lead to dissociation and inactivation of C3b from the classical and alternative pathway convertases. Mirococept effectively blocks and reduces the generation of the activated form of C3, and thwarts the release of both C3a and C5a.
Innovators Monograph
You find simplified version here Mirococept
